Dec 29, 2025 • MarketBeat
NEUTRAL
Farther Finance Advisors LLC Makes New $1.14 Million Investment in Summit Therapeutics PLC $SMMT
Farther Finance Advisors LLC has invested $1.14 million in Summit Therapeutics PLC, acquiring 55,236 shares in Q3. This new institutional investment follows significant insider buying, with CEOs Mahkam Zanganeh and Robert W. Duggan each purchasing 26,680 shares. Despite missing Q3 earnings estimates, analysts maintain a "Moderate Buy" rating for SMMT with an average price target of $31.77.
Dec 28, 2025 • MarketBeat
SOMEWHAT-BULLISH
Capricorn Fund Managers Ltd Takes $10.25 Million Position in Summit Therapeutics PLC $SMMT
Capricorn Fund Managers Ltd acquired a new position of 496,266 shares in Summit Therapeutics PLC (NASDAQ:SMMT) valued at approximately $10.25 million, making it their 9th largest holding. Insider buying has been significant, with the CEO and a director purchasing shares worth around $10.5 million, raising insider ownership to 84.90%. Despite a mixed analyst sentiment with a "Moderate Buy" consensus and a $31.77 target price, the company missed its recent quarterly EPS expectations.
Dec 24, 2025 • Oncodaily
BULLISH
Closing the Year With Gratitude and Shared Purpose – Summit Therapeutics
Summit Therapeutics shared a message on LinkedIn, expressing gratitude and reflecting on the importance of people in making progress possible. The company thanked its supporters for their dedication and belief, which drives meaningful impact. They concluded by wishing everyone a joyful and peaceful holiday season.
Dec 22, 2025 • Simply Wall Street
NEUTRAL
The Bull Case For Summit Therapeutics (SMMT) Could Change Following Ivonescimab’s HARMONi-3 Phase 3 Spotlight - Learn Why
Cantor Fitzgerald reiterated an Overweight rating and Barclays upgraded to Equalweight for Summit Therapeutics, highlighting ivonescimab’s planned late-2025 BLA submission and the HARMONi-3 Phase 3 lung cancer study in 2026. This focus on the HARMONi-3 trial could significantly alter the investment narrative for SMMT. Investors are weighing the blockbuster potential against the risks of prolonged unprofitability and sensitivity to any trial setbacks.
Dec 22, 2025 • Simply Wall Street
SOMEWHAT-BULLISH
The Bull Case For Summit Therapeutics (SMMT) Could Change Following Ivonescimab’s HARMONi-3 Phase 3 Spotlight - Learn Why
Cantor Fitzgerald reiterated an Overweight rating and Barclays upgraded Summit Therapeutics to Equalweight, highlighting the upcoming late-2025 Biologics License Application submission for ivonescimab and the pivotal HARMONi-3 lung cancer study expected in 2026. These endorsements emphasize ivonescimab's central role in the biotech conversation around oncology assets, potentially reshaping Summit Therapeutics' investment narrative despite current losses and reliance on external capital. The focus on these key milestones clarifies catalysts but also raises the execution bar for the company.
Dec 21, 2025 • MarketBeat
SOMEWHAT-BULLISH
Summit Therapeutics PLC (NASDAQ:SMMT) Given Average Rating of "Moderate Buy" by Brokerages
Summit Therapeutics PLC (NASDAQ:SMMT) has received an average "Moderate Buy" rating from eighteen brokerages, with an average 12-month target price of $31.77. Insider activity shows significant buying by CEO Robert Duggan and Director Yu Xia in the last 90 days, with insiders owning approximately 84.9% of the company. The company recently missed quarterly EPS estimates but analysts predict a -0.3 EPS for the current fiscal year.